Invited Editorials
Vol. 1 No. 1 (2022)
Milvexian and other drugs targeting Factor XI: a new era of anticoagulation?
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 15 April 2022
2136
Views
576
Downloads
Authors
For almost 90 years, the discovery and development of anticoagulant drugs have focused on maximizing their antithrombotic efficacy while minimizing the risk of bleeding, in addition to providing manageable compounds with predictable and/or monitorable effects [...].
Downloads
Download data is not yet available.
Citations
Sanghai S, Wong C, Wang Z, et al. Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: The SAGE-AF Study. J Am Heart Assoc 2020;9:e014108. DOI: https://doi.org/10.1161/JAHA.119.014108
Trujillo-Santos J, Di Micco P, Dentali F, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost 2017;117:382-9. DOI: https://doi.org/10.1160/TH16-07-0494
Hsu C, Hutt E, Bloomfield DM, et al. Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. J Am Coll Cardiol 2021;78:625-31. DOI: https://doi.org/10.1016/j.jacc.2021.06.010
Fredenburgh JC, Weitz JI. New anticoagulants: Moving beyond the direct oral anticoagulants. J Thromb Haemost. 2021 Dec 30. doi: 10.1111/jth.15631 DOI: https://doi.org/10.1111/jth.15126
Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015;372:232-40. DOI: https://doi.org/10.1056/NEJMoa1405760
Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the foxtrot randomized clinical trial. JAMA 2020;323:130-9. DOI: https://doi.org/10.1001/jama.2019.20687
Verhamme P, Yi BA, Segers A, et al. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med 2021;385:609-17. DOI: https://doi.org/10.1056/NEJMoa2105872
Weitz JI, Strony J, Ageno W, et al. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med 2021;385:2161-72. DOI: https://doi.org/10.1056/NEJMoa2113194
Lorentz CU, Tucker EI, Verbout NG, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood 2021;138:2173-84. DOI: https://doi.org/10.1182/blood.2021011725
How to Cite
1.
Donadini MP, Ageno W. Milvexian and other drugs targeting Factor XI: a new era of anticoagulation?. Bleeding Thromb Vascul Biol [Internet]. 2022 Apr. 15 [cited 2025 Nov. 9];1(1). Available from: https://www.btvb.org/btvb/article/view/22
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Share
Similar Articles
- PO93 | Use of DOACS in heart transplantation recipients , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Marialaura Bonaccio, Licia Iacoviello, Maria Benedetta Donati, It’s definitely time to consider diet in its ultra-processing form as a major risk factor for thrombotic vascular disorders , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- CS04 | Association between elevated plasma levels of tissue plasminogen activator and occult cancer risk: a nested case-cohort analysis in 10,294 healthy subjects , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO92 | Challenging management of portal vein thrombosis in a cirrhotic patient on hormone therapy after breast cancer , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO47 | Hemophilia A and antithrombin deficiency: a case of natural hemostatic rebalancing , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Maria J. Fernandez Turizo, Rushad Patell, Jeffrey I. Zwicker, Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Matteo Guarascio, Gerardo Nicola Pititto, Alessia Abenante, Marco Paolo Donadini, Distal deep vein thrombosis: is there a way out of this dark forest? , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- PO94 | The use of antidepressant drugs and benzodiazepine hypnotics as an unusual risk factor for VTE , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO61 | ACTN1-related thrombocytopenia and severe hyperhomocysteinemia: a case report , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO08 | Efficacy and safety of thromboprophylaxis in hospitalized hematological patients: a monocenter retrospective study , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Daniela Poli, Walter Ageno, Emilia Antonucci, Salvatore Bradamante, Eugenio Bucherini, Paolo Chiarugi, Antonio Chistolini, Benilde Cosmi, Anna Falanga, Antonio Insana, Domenico Lione, Rosa Maria Lombardi, Giuseppe Malcangi, Rossella Marcucci, Giuliana Martini, Lucilla Masciocco, Carmelo Paparo, Daniele Pastori, Simona Pedrini, Vittorio Pengo, Pasquale Pignatelli, Andrea Toma, Sophie Testa, Gualtiero Palareti, Management of anticoagulation in atrial fibrillation patients in Italy: insight from the Atrial Fibrillation-Survey on Anticoagulated Patients Register (AF-START) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Gualtiero Palareti, Paolo Prandoni, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Alberto Tosetto, Lorenza Bertù, Sophie Testa, Vittorio Pengo, Walter Ageno, Ida Martinelli, Benilde Cosmi, Eugenio Bucherini, Daniela Poli, Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Giuseppe Camporese, Paolo Prandoni, Walter Ageno, Aspirin or low-molecular weight heparin for thromboprophylaxis after a fracture? That is the question , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Martina Berteotti, Walter Ageno, Rossella Marcucci, Andrea Stella, Paolo Zamboni, Romeo Martini, The role of dyslipidemia and gender-related risk factors in the management of patients with abdominal aortic aneurysms: a survey from the Italian Society of Angiology and Vascular Medicine and a call to action , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 2 (2025)
